and as this acquisition i mean fair for shareholders many were previously expecting allegan to split in order to push shareholder value and activists investors were pressuring the company to separate out its chairman versus the seal roles as currently both are actually held by brant saunders. raymond james analyst said that it's like christmas in june for allegan so many think it's a good deal but i think as investors it depends on where you bought it the 52 week high on allegan this year was 197 it was trading at like 114116 before the deal went through maybe a little higher and it's up almost 40 points on the news so if you bought it lower than you're happy if you paid in the $19.00 these you're not happy but overall they missed out on the bigger deal the $63000000000.00 deal is probably the best they could have got right now and i'm right now this deal looks like essentially temporary band-aid or perhaps a blood infusion for as it loses their exclusive rights to humira humira accounting for more than half of the company's revenues can elegans pipeline make up for that loss. blood

with each other for preeminence saunders the currency oh of allergan and legendary deal maker group allegan when he was named c.e.o. of forest labs 5 months later he sold forest to activists for $25000000000.00 then acquired al again for over $70000000000.00 and took on its name with more on this transformative act with welcome back adam mesh c.e.o. of the adam mesh trading group so adam this is certainly a big day for allergen in 2016 allegan had attempted to sell themselves to pfizer in $160000000000.00 merger but that deal ultimately fell through so the question is will this deal close we know that bristol myers and sullivan have been delayed due to antitrust concerns so will add they are allegan need to divest any of its assets to push this through. i think they'll definitely have to divest us as they proactively announce that they're going to do so they definitely will it's a question of how much and we know from the bristol myers celgene deal that they had to invest a monday bristol myers announced that they're divesting want to sell jeans top products to avoid those antitrust issues

but i think as investors it depends on where you bought it the 52 week high on allegan this year was 197 it was trading at like 114116 before the deal went through maybe a little higher and it's up almost 40 points on the news so if you bought it lower than you're happy if you paid in the $19.00 these you're not happy but overall they missed out on the bigger deal the $63000000000.00 deal is probably the best they could have got right now and i'm right now this deal looks like essentially temporary band-aid or perhaps a blood infusion for as it loses their exclusive rights to humira humira accounting for more than half of the company's revenues can elegans pipeline make up for that loss. blood and dues and that's good for the bottom there yes you know it will it can do is it will add new products and rather than. rather than saving it it is more of a ban it does buy them more time. which is important as they need to come out with more products on their own so yes this isn't a killer this is a band-aid but it's a time bind and it. and now the entire. up today even with the market down

we had the deal this morning with abby buying allegan for -- with abbvie buying allegan for $63 billionme investors think there could be a problem. here's that rally for the new zealand dollar, up 2.5%, the longest streak since last year. this probably has more to do with dollar weakness, and that has to do with the dovish town of central banks. guy: thank you very much indeed. let's talk about natixis. the stock is down again today. this is as we keep an eye on what is happening with the latest data surrounding h2o, the london-based investment firm which natixis has the letter -- has, theoretically, a relationship with. let's talk about where the data is going to take us next. bloomberg credit reporter numbers were -- credit reporter, is worth -- our bloomberg credit reporter joins us now on set. when are we going to get the next set of data, and what do you expect? reporter: it is taking about one working day or just a little more for the number to come out, so we should find out later today or possibly early tomorrow what the number was for monday. wednesday through friday last week,

know that bristol myers and sullivan have been delayed due to antitrust concerns so will add the or allegan need to divest any of its assets to push this through. i think the devil may have to divest us as they've proactively announced that they're going to do so for example we will. it's a question of how much and we know from the bristol myers celgene deal that they had the best in fact on monday bristol myers announced that their divesting want to sell jeans top products to avoid those antitrust issues and the government's taking a more conservative approach so it's definitely going to be an issue and it's smart they brought that up because that's something that we're going to look out for. and on this and position will return the company in the us after heading completed its tax inversion deal to ireland in 2015 something we've seen apple do to great effect as well saving the company hundreds of millions in taxes and you really this is a good move for l. again. so inversions were a big deal a couple of years ago than the government took measures to make it a little more difficult to do

drug maker abby announced it will acquire botox maker allegan for about 63000000000 dollars gaining control of the biggest name in medical as in order to reduce its reliance on key arthritis treatment humira abby has been under pressure to diversify its portfolio as humira the world's best selling drug posted its 1st ever drop in worldwide sales this year as it face competition from cheaper biosimilars in europe under the terms of the deal they will pay point 866 of its shares and $12030.30 in cash for each share of allergen marking a 45 percent premium share price this deal comes as the latest in a string of acquisitions for the pharmaceutical industry as they began consolidating earlier this year bristol myers purchased sell a gene for $74000000000.00 and eli lilly bought locke's oncology for $8000000000.00 this is not a typical big pharma for the last 3 decades 2 radically different couple spending activities and the neighbors as r. and d. have jostled with each other for preeminence saunders the currency oh of allergan and legendary deal maker group allegan when he was named c.e.o. of.

abbvie buying allegan. david: all they say they are going to be -- although they say they are going to be accretive. alix: peak accretion greater than 20%. those are pretty staggering numbers. david: they are paying a premium of 45%. alix: we are going to keep following this and what it means for other health care in a day -- other health care m&a. in the markets, sb futures pause until the g20 -- s&p futures pause until the g20. the dollar hit a three-month low yesterday. 2%.ds did dip below now we are back about that. crude a little softer. it feels like a teeny bit of a risk off on the margins, but nothing extreme. david: a lot to digest. go to the morning brief. at 8:30 eastern, we get u.s. new-home sales data for may. throughout the day, we hear from a range of said speakers, starting with jay powell, williams, bostic, and parkland. bullards then-president will be on bloomberg radio and a conversation with kathleen hays. the best treasury will be selling $4 billion in two-year notes. at the bell, we wi

drugmaker abbey announced it will the choir botox maker allegan for about 63000000000 dollars gaining control of the biggest name in medical aesthetics in order to reduce its reliance on key arthritis treatment humira as the has been under pressure to diversified portfolio as humira the world's best selling drug posted its 1st ever drop in worldwide sales this year as a face competition from cheaper biosimilars in europe under the terms of the deal at the well pay point $86.00 of its shares and $12030.30 in cash for each share of allergen marking a 40.

that day karma is back in the spotlight as a native american it's now official advocate has stepped allegan and walk past them to add a mash of the atom match trading they're standing by to break down the deal and if that's true with some partners find that stuff was. a lot as at present they are set to be at the g. 20 in japan later this week where they have are hoping a product of its offering trade and terrified r.t. correspondent alex ahead of it on hand to help us for through what lies in the are for markets and finally as we see global markets in are uncertain territory one precious metal regain that shine peter schiff of euro pacific capital will be joining us to dig into gold's recent tear and what's causing the glow that got a bad show to those who let's go and dive right in. drugmaker abbey announced there while the choir botox maker for about $63.00. 1000000000 dollars gaining control of the biggest name in medical aesthetics in order to reduce its reliance on key arthritis treatment humira as the has been under pressure to diversified portfolio as humira the world's best selling

>> yeah, i think this is going to go through because allegan has been looking to break up, the sharet year and only gotten bid, pretty interesting because advi if you look at it they actually have the world's best selling drug so ending patent protection and marriage makes sense for both sides, i think it does go through. maria: that's when you see a lot of deals, when patent expiration >> beauty drugs, botox, indeed, baby boomers looking to enjoy themselves, look good, feel good, the market for the products is going in billions. maria: you're right, incredible market for botox, allergan was top performer, last year was underperforming. >> it's important to know that this is a cash and stock deal, it's going to be interesting when they come out with the deal who is actually going to lead the company because ben sanders has done a good job for the past year and hasn't done well for ceo. >> yeah, i remember when he was on the cover, i think it was fortune magazine talking about allergan an his success, abbvie down near 6%, nearing deal to acquire allergan for more than $60 million cash

allegan shock -- stock is nowhere near the offer price and abbvie is down near 50%. question is is this a band-aid? yes abbvie is getting diversification, but the sales declines they will see with hume era is a long-term problem. they are paying a lot of money for that, taking the 10th largest loan on record to finance the m&a. we saw with the bristol-myers squibb celgene deal top investors putting back on the deal, and eventually it did go through but at a much lower price. in as ftc going to get this is a very big deal? vonnie: kailey leinz, thank you for that. time for our latest bloomberg business flash. a look at the latest business stories in the news. nissan is pledging to put more focus on fixing its troubled alliance with renault. to japanese carmaker voted give the french company more say over its future. andult owns 40% of nissan is getting more representatives on keyboard committees. in norway, the country's trillion dollar sovereign wealth fund has ended its ban on investing in walmart. that had lasted more than a decade. the funds fx county says the lar

allegan rising 25%.s are split on the efficacy, but it should not m&a.ct from a huge boom in it means quarterly deal volume and deal value is that a record high. watchers whoy m&a expect more of this given the relative low cost of debt-financed and the amount of cash that remains. >> thanks. breaking news. micron earnings out. the top lineeat on numbers. shares moving higher. adjusted revenue at $7.49 billion. gross margin at $39.3 billion versus 60.9 billion dollars in the previous year. eps was 105. 107.stimate was >> we are starting to get earnings. where peoplelement are saying watch the second quarter. or -- is the first, among the first report. picturell get a mixed second quarter. that's why i'm not too bearish. abigail's chart could make since. , theld see some positivity earnings providing a mixed picture, but the guidance will be interesting to watch. i think it will be negative and we will start slashing forecasts in the third quarter. joe: what is your view on earnings? you think investors ar

abbvie buying allegan. david: all they say they are going to be -- although th